Technology

Discover how our Self-Emulsifying Nano-Delivery System transforms oil-based actives into ultra-stable, ultra-bioavailable formulations—without specialty equipment.

Self-Emulsifying Nano-Delivery Mechanism

🧪 Instant Emulsion Formation

Upon contact with water or biological fluids, SENDS™ spontaneously forms a uniform oil-in-water nano-emulsion, eliminating the need for high-shear mixers or heat treatment (sendstechnology.com).

⚡ Nano-Scale Droplets

(<100 nm): These ultra-fine droplets maximize surface area, driving rapid absorption across topical, mucosal, and gastrointestinal barriers (sendstechnology.com).

🧴 Versatile Matrix:

The single-phase SENDS™ matrix remains homogenous in both oil- and water-based systems, ensuring seamless integration into liquids, creams, patches, or powders (sendstechnology.com).

Our Formulation Workflow

Our collaborative, five-step process guarantees a tailored SENDS™ solution ready for scale:

N

Step 1

Product Discovery and Evaluation

Step 2

Needs Assessment and Specifications

Step 3

Formulation Design and Iteration

Step 4

Sampling, Testing and Feedback

Step 3

Manufacturing Partnership and Scale-Up

Stability and Shelf-Life Data

🧪 24-Month Integrity

Rigorous stability studies demonstrate <1% degradation of loaded actives after two years at 25 °C, safeguarding potency and performance (sendstechnology.com).

🚫 THC Conversion Prevention

 By maintaining a protective nano-matrix, SENDS™ minimizes degradation pathways that can produce unwanted byproducts.

📦 Consistent Quality

Long-term stability ensures reliable dosing and shelf presence across diverse product formats.

Patent and IP Overview

Globally Patented Technology

Developed by Dr. Noi Obias, SENDS™ is safeguarded by international patents, ensuring exclusive use and unmatched innovation.

Freedom to Operate

License SENDS™ confidently, knowing our patents cover essential self-emulsification processes and formulation techniques.

Ongoing Innovation

Continuous R&D expands applications, with new patent filings under review for targeted delivery enhancements.